Trial · NCT02513498
Adverse events47
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 47
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | amylase increased | Investigations | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | constipation | Gastrointestinal disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | diarrhea | Gastrointestinal disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | fatigue | General disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | headache | Nervous system disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | hyperglycemia | Metabolism and nutrition disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | hypertriglyceridemia | Metabolism and nutrition disorders | Treatment (Ixazomib Citrate) | 2 | 50 | 3 |
| other | hyponatremia | Metabolism and nutrition disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | hypophosphatemia | Metabolism and nutrition disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | influenza a | Infections and infestations | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | leg pain | Musculoskeletal and connective tissue disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | lipase increased | Investigations | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | lymphopenia | Blood and lymphatic system disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | muscle weakness | Musculoskeletal and connective tissue disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | peripheral neuropathy | Nervous system disorders | Treatment (Ixazomib Citrate) | 2 | 50 | 2 |
| other | otomastoiditis | Ear and labyrinth disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | pneumonia | Respiratory, thoracic and mediastinal disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | restlessness | Nervous system disorders | Treatment (Ixazomib Citrate) | 1 | 50 | 1 |
| other | skin infection | Infections and infestations | Treatment (Ixazomib Citrate) | 1 | 50 | 2 |
| other | thrombocytopenia | Blood and lymphatic system disorders | Treatment (Ixazomib Citrate) | 3 | 50 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02513498/events